Toni Martinez

Postdoc | The Francis Crick Institute & Barts Cancer Institute | Cancer evolution, somatic mutations, TP53 & colorectal cancer 🧬

[Toni Martinez @MartinezToni2]

🧬 Weekly report: p53 mutations & anti-cancer therapy response

Highlight: broad reactivation of mutant p53 using DARPins

https://t.co/FvOGfwvoxg

@Bims_BiomedNews

#p53 #Oncology #PrecisionMedicine

[Toni Martinez @MartinezToni2]

Mutant p53 & therapy response weekly report 🧬

Highlight: Low-penetrance TP53 variants are mainly hypomorphic

Not all TP53 mutations are equal, some retain partial function with real clinical impact.

@Bims_BiomedNews

https://t.co/83THo3AwDN

#p53 #CancerResearch

[Toni Martinez @MartinezToni2]

🧬 Mutant p53 & therapy response - Weekly report

🔬 Highlight: Covalent agonists targeting p53 Y220C restore its function and suppress tumor growth - real progress toward drugging mutant p53.

👉 https://t.co/FvOGfwvoxg

@Bims_BiomedNews

#p53 #Oncology

[Toni Martinez @MartinezToni2]

Mutant p53 & therapy response - weekly report 🧬

🔬 Highlight: TP53 mutations may predict poor response to taxane chemotherapy

TP53 status isn’t just biology, it’s clinical.

@Bims_BiomedNews

#p53 #CancerResearch #Oncology

https://t.co/UaKbsylkou

[Toni Martinez @MartinezToni2]

🧬 New report: Mutant p53 & cancer therapy

- TP53 CpG site mutations define an immune-activated tumor subtype and predict improved response to first-line chemoimmunotherapy in lung adenocarcinoma.

@Bims_BiomedNews

#p53 #CancerResearch #Immunotherapy

https://t.co/ZX6tafLHth

[Toni Martinez @MartinezToni2]

🧬 New report: Mutant p53 & anti-cancer therapy response

Highlights:
- TP53 loss links mTOR activation and immune-cold MSS colorectal cancer
- TP53 mutations associate with improved PFS with cetuximab+pembrolizumab in CRC

@Bims_BiomedNews

#p53
https://t.co/bZdm89rSZ4

[Toni Martinez @MartinezToni2]

🧬New Mutant p53 & Cancer Research Report of the week!
Highlights:

- TP53-mut diffuse follicular lymphoma with cnLOH at 1p36 highlights molecular profiling.
- Mut p53 rewires CXCL10, boosting CD8⁺ T cells and anti-PD-1 response.

@Bims_BiomedNews

https://t.co/8WhRg1Ogd5

[Toni Martinez @MartinezToni2]

New Mutant p53 & Cancer Therapy Response Report is out! 🧬

Highlights:

• Lung-specific p53 mutants bind DNA but fail to transactivate

• Rezatapopt shows Phase I activity in Y220C tumors

@Bims_BiomedNews

#p53 #CancerResearch #Oncology

https://t.co/nJQCOQs8pM

[Toni Martinez @MartinezToni2]

New weekly Mutant p53 & Anti-Cancer Therapy Response report out now 🧬🧠

This issue highlights:

- Novel drug and prodrug candidates targeting TP53 mutations
- TP53-dependent cell fate in glioblastoma

@Bims_BiomedNews

https://t.co/oNm874vP3c

#p53 #Oncology #CancerResearch

[Toni Martinez @MartinezToni2]

New week, new report 🧬

My weekly Mutant p53 & anti-cancer therapy response report is out.

Fresh evidence on how TP53 mutations shape treatment response in cancer.

@Bims_BiomedNews

#p53 #Cancer #Oncology #CancerTherapy #BiomedsNews

https://t.co/YEeaQ9Pi8E

[Docusalut @docusalut]

Nou article a #Docusalut: Hotspot mutant p53-R273H enhances mitochondrial biogenesis and cell migration in primary colorectal cancer in response to oxaliplatin https://t.co/313a7Wv4ah  @idisbaib #PublicaSalutIB

[Toni Martinez @MartinezToni2]

Highlight:

"Pro-ATO/Allicin Liposomes for Dual-Pathway Targeting of p53-Mutant Tumors"

https://t.co/QdjU3Lg3aY

[Toni Martinez @MartinezToni2]

A new Biomeds News report is out 🚀

This week’s update on mutant p53 & anti-cancer therapy response - key papers, one place.

@Bims_BiomedNews

#p53 #CancerResearch #Oncology #BiomedsNews

https://t.co/J0JksaZJkf

[Docusalut @docusalut]

Nou article a #Docusalut: Hotspot mutant p53-R273H enhances mitochondrial biogenesis and cell migration in primary colorectal cancer in response to oxaliplatin  https://t.co/NrCazO360N  @idisbaib #PublicaSalutIB

[Toni Martinez @MartinezToni2]

Highlight:

"Efficacy of melflufen in multiple myeloma with mutated or deleted TP53"

https://t.co/RShEWunM21

[Toni Martinez @MartinezToni2]

Here we go again! Kicking off 2026 🚀, my weekly report about mutant p53 and anti-cancer therapy response is out.

@Bims_BiomedNews

#p53 #Oncology #CancerTherapy #BiomedsNews

https://t.co/qJyxOWa3pz

[Toni Martinez @MartinezToni2]

Highlight:
https://t.co/3WZzmEjS7q

[Toni Martinez @MartinezToni2]

Just before Christmas🎄, my weekly Biomeds News report is out.

Growing evidence shows the clinical relevance of mutant p53 in treatment response, positioning it as a key axis in anticancer therapy.

@Bims_BiomedNews

#p53 #Oncology #biomedsnews

https://t.co/FioEYV1hla

[Toni Martinez @MartinezToni2]

Highlight:

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome

https://t.co/IfAuD4FWTg

[Toni Martinez @MartinezToni2]

🧬Mutant p53 & anticancer therapy - weekly update.

A curated snapshot of recent studies on therapy response, resistance and tumour adaptation across cancers.

https://t.co/WPlm5H9HHi

@Bims_BiomedNews

#p53 #Oncology #CancerResearch